Clinical trials: Herpes Simplex
Herpes Zoster
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course.
- Trial name
- NCT02735915
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Chlamydia Trachomatis
Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide
The primary aims of the study were to assess the safety and acceptability of PC-515 when applied vaginally at least three times weekly for 12 months.
- Conditions
- HIV Infections, Chlamydia Trachomatis, Neisseria Gonorrhoeae, Trichomonas Vaginitis
- Trial name
- NCT00213031
- Testing
- Carraguard (PC-515)
- Where
- Thailand
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Population Council
Photodynamic Therapy, Herpes Simplex, Labial
Treatment of Herpes Labialis by Photodynamic Therapy
Lesions of herpes labialis are caused by the herpes simplex virus type 1 (HSV-1) and cause pain and aesthetic compromise. It is characterized by the formation of small vesicles that coalesce and rupture forming extremely painful…
- Trial name
- Herpes (NCT04037475)
- Testing
- photodynamic therapy herpes labialis
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Nove de Julho
Shingles, Herpes Zoster Infection
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV…
- Conditions
- Shingles, Herpes Zoster Infection, Human
- Trial name
- NCT05703607
- Testing
- Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
- Where
- 35 sites in United States
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bacterial Vaginosis
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
This investigation assessed the effects of asymptomatic BV on daily genital tract shedding of HSV-2 by determining shedding frequency before and after treatment of asymptomatic BV.
- Trial name
- MASH (NCT00464542)
- Testing
- Metronidazole
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
HIV, Herpes Simplex Infections
Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV
The purpose of this study is to assess the safety and pharmacokinetics of MB66, a monoclonal antibody film for vaginal application that is being developed to potentially reduce the transmission of herpes simplex virus (HSV) and…
- Trial name
- VAST (NCT02579083)
- Testing
- MB66
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- KBio Inc
Herpes
A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)
To evaluate the safety and tolerability of different dosages of recombinant zoster vaccine (CHO cell) when administered to adults aged 40 years and older.
- Trial name
- NCT07633197
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Herpes Zoster, Postherpetic Neuralgia
Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo
The purpose of this study is to see if therapy with the drug pregabalin relieves pain during shingles compared with placebo. A placebo is an inactive substance.
- Trial name
- NCT00352651
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Anogenital Herpes, COVID-19
Viral Infections in Healthy and Immunocompromised Hosts
Background: Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems.
- Conditions
- Anogenital Herpes, COVID-19, Herpes Labialis
- Trial name
- NCT01306084
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes
Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Famciclovir 500 mg Tablets under fed conditions.
- Trial name
- NCT01321502
- Testing
- famciclovir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Aging, Herpes Zoster
Shingles: Immune Effects of Tai Chi
The purpose of this trial is to evaluate the effects of Tai Chi Chih versus Health Education on shingles immunity in older adults as measured by unstimulated and vaccine-stimulated responses.
- Trial name
- NCT00118885
- Testing
- Tai Chi Chih
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT06954818
- Testing
- A zoster mRNA vaccine SYS6017
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Prevention of : Herpes-Zoster
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
Primary objective: Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month…
- Trial name
- NCT00561080
- Testing
- Zostavax
- Volunteers
- 759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Herpes
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
- Trial name
- NCT07330440
- Testing
- Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Herpes Zoster
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.
- Trial name
- NCT05856084
- Testing
- Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster Vaccine (CHO cells), Positive control
- Where
- China
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum
Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum
This study investigates whether blood monocytes' surface bound- immunoglobulin E affects the innate immune responses against herpes simplex viruses in atopic dermatitis patients with eczema herpeticum.
- Conditions
- Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
- Trial name
- NCT04060550
- Testing
- Xolair
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Herpes Zoster
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
The study evaluated immunogenicity, safety, and tolerability of ZOSTAVAX™ Vaccine (V211) administered concomitantly versus nonconcomitantly with Quadrivalent Influenza Virus vaccine (inactivated) in participants ≥50 years of age.
- Trial name
- NCT02519855
- Testing
- ZOSTAVAX™, Influenza Vaccine
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged >=50 years of age.
- Trial name
- RSV-OA=ADJ-020 (NCT05966090)
- Testing
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Where
- 31 sites in United States, Canada
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox, Herpes Zoster
Immune Response to Varicella-Zoster Vaccination and Infection
Background: The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease.
- Trial name
- NCT00921999
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)